{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:22:46Z","timestamp":1787750566044,"version":"build-2784847793"},"reference-count":97,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T00:00:00Z","timestamp":1534723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Treatment of superficial fungal infections has come a long way. This has, in part, been through the development and evaluation of new drugs. However, utilising new strategies, such as identifying variation between different species in responsiveness, e.g., in tinea capitis, as well as seeking better ways of ensuring adequate concentrations of drug in the skin or nail, and combining different treatment methods, have played equally important roles in ensuring steady improvements in the results of treatment. Yet there are still areas where we look for improvement, such as better remission and cure rates in fungal nail disease, and the development of effective community treatment programmes to address endemic scalp ringworm.<\/jats:p>","DOI":"10.3390\/jof4030099","type":"journal-article","created":{"date-parts":[[2018,8,20]],"date-time":"2018-08-20T11:23:06Z","timestamp":1534764186000},"page":"99","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["Therapy of Skin, Hair and Nail Fungal Infections"],"prefix":"10.3390","volume":"4","author":[{"given":"Roderick","family":"Hay","sequence":"first","affiliation":[{"name":"Kings College London, London SE5 9RS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0190-9622(08)81495-8","article-title":"Antifungal agents: An overview. Part I","volume":"30","author":"Gupta","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0190-9622(94)70112-1","article-title":"Antifungal agents: An overview. Part II","volume":"30","author":"Gupta","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","first-page":"CD001434","article-title":"Topical treatments for fungal infections of the skin and nails of the foot","volume":"3","author":"Crawford","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1001\/jamadermatol.2013.1721","article-title":"Efficacy of topical antifungals in the treatment of dermatophytosis: A mixed-treatment comparison meta-analysis involving 14 treatments","volume":"149","author":"Rotta","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00003495-199855050-00004","article-title":"An overview of topical antifungal therapy in dermatomycoses. A North American perspective","volume":"55","author":"Gupta","year":"1998","journal-title":"Drugs"},{"key":"ref_6","first-page":"38","article-title":"Increasing Patient Adherence in Antifungal Infection Treatment","volume":"2","author":"Weinberg","year":"2009","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_7","first-page":"154","article-title":"Randomised controlled trial of topical butenafine in tinea cruris and tinea corporis Indian J","volume":"69","author":"Ramam","year":"2003","journal-title":"Dermatol. Venereol. Leprol."},{"key":"ref_8","first-page":"4","article-title":"Ciclopirox (Loprox) gel for superficial fungal infections","volume":"9","author":"Gupta","year":"2004","journal-title":"Skin Ther. Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00006454-199706000-00002","article-title":"Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris","volume":"16","author":"Bakos","year":"1997","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00128071-200708060-00007","article-title":"Comparative study of 2% sertaconazole solution and cream formulations in patients with tinea corporis, tinea pedis interdigitalis, or a corresponding candidosis","volume":"8","author":"Borelli","year":"2007","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000249910","article-title":"Treatment of Dermatomycoses with Topical Tioconazole and Miconazole","volume":"166","author":"Fredriksson","year":"1983","journal-title":"Dermatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003495-198835020-00004","article-title":"Sulconazole A Review of its Antimicrobial Activity and Therapeutic Use in Superficial Dermatomycoses","volume":"35","author":"Benfield","year":"1988","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4103\/0019-5154.105284","article-title":"Comparative assessment of the efficacy and safety of sertaconazole (2%) cream versus terbinafine cream (1%) versus luliconazole (1%) cream in patients with dermatophytoses: A pilot study","volume":"58","author":"Jerajani","year":"2013","journal-title":"Indian J. Dermatol."},{"key":"ref_14","first-page":"E70","article-title":"Isoconazole nitrate vs isoconazole nitrate and diflucortolone valerate in the treatment of tinea inguinalis: Results of a multicenter retrospective study","volume":"11","author":"Veraldi","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1365-2133.2012.10815.x","article-title":"Efficacy and safety of topical antifungals in the treatment of dermatomycosis: A systematic review","volume":"166","author":"Rotta","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_16","first-page":"CD009992","article-title":"Topical antifungal treatments for tinea cruris and tinea corporis","volume":"8","author":"Fedorowicz","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000246173","article-title":"Tinea pedis: Clinical experience and efficacy of short treatment","volume":"194","author":"Evans","year":"1997","journal-title":"Dermatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1439-0507.2001.00672.x","article-title":"Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study","volume":"44","author":"Budimulja","year":"2001","journal-title":"Mycoses"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/j.1468-3083.2006.01807.x","article-title":"Efficacy and safety of a new single-dose terbinafine 1% formulation in patients with tinea pedis (athlete\u2019s foot): A randomized, double-blind, placebo-controlled study","volume":"20","author":"Ortonne","year":"2006","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","first-page":"1004","article-title":"Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream and gel, 2%","volume":"12","author":"Plaum","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.0933-7407.2001.00653.x","article-title":"Butenafine hydrochloride (Mentax) cream for the treatment of hyperkeratotic type tinea pedis and its transfer into the horny layer, with or without concomitant application of 20% urea ointment (Keratinamin)","volume":"44","author":"Tanuma","year":"2001","journal-title":"Mycoses"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2133.1994.tb06089.x","article-title":"Two-week oral treatment of tinea pedis, comparing terbinafine (250 mg\/day) with itraconazole (100 mg\/day): A double-blind, multicentre study","volume":"130","author":"Keyser","year":"1994","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/0190-9622(90)70253-E","article-title":"Itraconazole in common dermatophyte infections of the skin: Fixed treatment schedules","volume":"23","author":"Saul","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","first-page":"CD003584","article-title":"Oral treatments for fungal infections of the skin of the foot","volume":"10","author":"Khan","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0190-9622(08)81263-7","article-title":"Current therapy of dermatophytosis","volume":"31","author":"Degreef","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_26","unstructured":"Clinicaltrials.gov (2018, June 01). Bioavailability Study of Lozanoc\u2122 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis 2016, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02755857."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1365-4362.1998.00541.x","article-title":"A comparison of the efficacy of oral fluconazole, 150 mg\/week versus 50 mg\/day, in the treatment of tinea corporis, tinea cruris, tinea pedis, and cutaneous candidosis","volume":"37","author":"Nozickova","year":"1998","journal-title":"Int. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017881","article-title":"Fluconazole in the treatment of tinea corporis and tinea cruris","volume":"196","author":"Stary","year":"1998","journal-title":"Dermatology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1093\/clinids\/14.Supplement_1.S77","article-title":"Therapy with Fluconazole for Tinea Corporis, Tinea Cruris, and Tinea Pedis","volume":"14","author":"Perera","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.amjmed.2015.10.029","article-title":"Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status","volume":"129","author":"Re","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1001\/jamadermatol.2014.2154","article-title":"Posaconazole Treatment of Extensive Skin and Nail Dermatophytosis Due to Autosomal Recessive Deficiency of CARD9","volume":"151","author":"Jachiet","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.dsi.2013.11.002","article-title":"Disseminated deep dermatophytosis caused by Trichophyton rubrum in deep dermatophytosis affecting the skin","volume":"32","author":"Cheng","year":"2014","journal-title":"Dermatol. Sin."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2133.2007.08420.x","article-title":"The efficacy of oral treatment with pramiconazole in tinea pedis and tinea cruris\/corporis: Two exploratory phase IIa trials","volume":"158","author":"Decroix","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1468-3083.2005.01212.x","article-title":"A phase I\/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis","volume":"19","author":"Gupta","year":"2005","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_35","unstructured":"Welshenbaugh, A.R., Angulo, D., and Ghannoum, M. (2007, January 17\u201320). Time kill activity of albaconazole against agents of onychomycosis and tinea capitis. Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E4380","DOI":"10.1136\/bmj.e4380","article-title":"The diagnosis and management of tinea","volume":"345","author":"Moriarty","year":"2012","journal-title":"BMJ"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/2229-5178.178099","article-title":"Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review","volume":"7","author":"Sahoo","year":"2016","journal-title":"Indian Dermatol. Online J."},{"key":"ref_38","unstructured":"(2018, June 01). WHO Guidelines on the Treatment of Skin and Oral HIV-Associated Conditions in Children and Adults World Health Organization. Available online: http:\/\/www.who.int\/maternal_child_adolescent\/documents\/skin-mucosal-and-hiv\/en\/."},{"key":"ref_39","unstructured":"Mandell, G.L., Bennett, J.E., and Dolin, R. (2015). Candida species. Principles and Practice of Infectious Diseases, Churchill Livingstone. [8th ed.]."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.2165\/11538110-000000000-00000","article-title":"Ciclopirox: Recent nonclinical and clinical data relevant to its use as a topical antimycotic agent","volume":"70","author":"Subissi","year":"2010","journal-title":"Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/10454411000110020301","article-title":"Oral candidal infections and antimycotics","volume":"11","author":"Ellepola","year":"2000","journal-title":"Crit. Rev. Oral Biol. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00003495-199039060-00006","article-title":"Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses","volume":"39","author":"Grant","year":"1990","journal-title":"Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2165\/00003495-198937030-00003","article-title":"Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses","volume":"37","author":"Grant","year":"1989","journal-title":"Drugs"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4248\/IJOS.09020","article-title":"Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China","volume":"1","author":"Sun","year":"2009","journal-title":"Int. J. Oral Sci."},{"key":"ref_45","first-page":"45","article-title":"Role of posaconazole in the treatment of oropharyngeal candidiasis","volume":"3","author":"Ianas","year":"2010","journal-title":"Infect. Drug Resist."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ijrobp.2010.02.006","article-title":"Candidoscope Study Group. Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: Results of the French CANDIDOSCOPE study","volume":"80","author":"Gligorov","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/archdermatol.2010.259","article-title":"Pityriasis versicolor: A systematic review of interventions","volume":"146","author":"Hu","year":"2010","journal-title":"Arch Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/jof1010013","article-title":"Antifungal Treatment for Pityriasis Versicolor","volume":"1","author":"Gupta","year":"2015","journal-title":"J. Fungi"},{"key":"ref_49","first-page":"283","article-title":"An open-label study of naftifine hydrochloride 1% gel in the treatment of tinea versicolor","volume":"9","author":"Gold","year":"2011","journal-title":"Skinmed"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1439-0507.2008.01508.x","article-title":"Comparative efficacy and tolerability of Ketomousse (ketoconazole foam 1%) and ketoconazole cream 2% in the treatment of pityriasis versicolor: Results of a prospective, multicentre, randomised study","volume":"51","author":"Martini","year":"2008","journal-title":"Mycoses"},{"key":"ref_51","first-page":"425","article-title":"A double-blind comparative study of sodium sulfacetamide lotion 10% versus selenium sulfide lotion 2.5% in the treatment of pityriasis (tinea) versicolor","volume":"73","author":"Hull","year":"2004","journal-title":"Cutis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00001432-200204000-00006","article-title":"Malassezia species in skin diseases","volume":"15","year":"2002","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/095466302317584421","article-title":"Fluconazole versus ketoconazole in the treatment of tinea versicolor","volume":"13","author":"Farschian","year":"2002","journal-title":"J. Dermatol. Treat."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1468-3083.1998.tb00781.x","article-title":"Short-term treatment of Pityrosporum folliculitis: A double-blind placebo-controlled study","volume":"11","author":"Parsad","year":"1998","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_55","first-page":"1713","article-title":"Seborrhoeic dermatitis","volume":"2010","author":"Naldi","year":"2010","journal-title":"Clin. Evid."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0190-9622(00)90001-X","article-title":"Tinea capitis: A current perspective","volume":"42","author":"Elewski","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_57","unstructured":"Fuller, C.F., Barton, R.C., and Mohd Mustapa, M.F. (2018, June 01). British Association of Dermatologists\u2019 Guidelines for the Management of Tinea Capitis. Available online: http:\/\/www.bad.org.uk\/shared\/get-file.ashx?id=2022&itemtype=document."},{"key":"ref_58","first-page":"CD004685","article-title":"Systemic antifungal therapy for tinea capitis in children","volume":"4","author":"Seaton","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jaad.2010.02.048","article-title":"Meta-analysis of randomized, controlled trials comparing griseofulvin and terbinafine in the treatment of tinea capitis","volume":"64","author":"Tey","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0190-9622(89)70331-5","article-title":"Evaluation of the carrier state in juvenile tinea capitis caused by Trichophyton tonsurans","volume":"21","author":"Babel","year":"1989","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_61","first-page":"189","article-title":"Tinea capitis","volume":"78","author":"Alvarez","year":"2006","journal-title":"Cutis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2230.1985.tb00537.x","article-title":"Tioconazole nail solution\u2014An open study of its efficacy in onychomycosis","volume":"10","author":"Hay","year":"1985","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-4362.1997.00024.x","article-title":"Treatment of onychomycosis: A randomized, double-blind comparison study with topical bifonazole-urea ointment alone and in combination with short-duration oral griseofulvin","volume":"36","author":"Cohen","year":"1997","journal-title":"Int. J. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies","volume":"68","author":"Elewski","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_65","first-page":"1186","article-title":"Efinaconazole topical, 10% for the treatment of toenail onychomycosis in patients with diabetes","volume":"13","author":"Vlahovic","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/AAC.02370-12","article-title":"Safety and Tolerability of Luliconazole Solution 10-Percent in Patients with Moderate to Severe Distal Subungual Onychomycosis","volume":"57","author":"Jones","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2230.1992.tb00281.x","article-title":"Amorolfine in the treatment of onychomycoses and dermatomycoses (an overview)","volume":"17","author":"Zaug","year":"1992","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1067\/mjd.2000.109071","article-title":"Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis","volume":"43","author":"Gupta","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"495","DOI":"10.7547\/87507315-90-10-495","article-title":"Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States","volume":"90","author":"Gupta","year":"2000","journal-title":"J. Am. Podiatr. Med. Assoc."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2015.04.010","article-title":"Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies","volume":"73","author":"Elewski","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/00128071-200304010-00005","article-title":"Terbinafine: A review of its use in onychomycosis in adults","volume":"4","author":"Darkes","year":"2003","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.1999.00008.x","article-title":"LION. Study: Efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis","volume":"141","author":"Sigurgeirsson","year":"1999","journal-title":"Br. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40257-013-0056-2","article-title":"Oral therapy for onychomycosis: An evidence-based review","volume":"15","author":"Lamas","year":"2014","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0190-9622(96)80057-0","article-title":"Treatment of dermatophyte nail infections: An open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy","volume":"34","author":"Tosti","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_75","first-page":"758","article-title":"Randomized, placebo-controlled, phase 3 study of itraconazole for the treatment of onychomycosis","volume":"12","author":"Maddin","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2133.2003.05728.x","article-title":"Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis","volume":"150","author":"Gupta","year":"2004","journal-title":"Br. J. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-4362.1998.00360.x","article-title":"Itraconazole for the treatment of onychomycosis","volume":"37","author":"Gupta","year":"1998","journal-title":"Int. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","article-title":"Onychomycosis: Pathogenesis, diagnosis and management","volume":"11","author":"Elewski","year":"1998","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0190-9622(98)70490-6","article-title":"Once-weekly fluconazole (150, 300, 450 mg) in the treatment of distal subungual onychomycosis of the toenail","volume":"38","author":"Scher","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2133.2011.10660.x","article-title":"A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis","volume":"166","author":"Elewski","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"E18158","DOI":"10.5812\/jjm.18158v2","article-title":"The Efficacy of Ultraviolet Irradiation on Trichophyton Species Isolated From Nails","volume":"8","author":"Nematollahi","year":"2015","journal-title":"Jundishapur J. Microbiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3109\/03639045.2011.568946","article-title":"Transungual delivery of terbinafine by iontophoresis in onychomycotic nails","volume":"37","author":"Nair","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.7863\/jum.2011.30.12.1723","article-title":"Ultrasound-mediated nail drug delivery system","volume":"30","author":"Abadi","year":"2011","journal-title":"J. Ultrasound Med."},{"key":"ref_84","first-page":"33","article-title":"Laser therapy of onychomycosis","volume":"12","author":"Nenoff","year":"2014","journal-title":"J. Dtsch Dermatol. Ges."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/myc.12225","article-title":"Laser treatment for onychomycosis: A review","volume":"57","author":"Bhatta","year":"2014","journal-title":"Mycoses"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jdv.13798","article-title":"Treating onychomycosis with the short-pulsed 1064-nm-Nd YAG laser: Results of a prospective randomized controlled trial","volume":"31","author":"Karsai","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1590\/abd1806-4841.20131932","article-title":"The use of the ER YAG 2940 nm laser associated with amorolfine lacquer in the treatment of onychomycosis","volume":"88","author":"Costa","year":"2013","journal-title":"An. Bras. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s10103-016-1990-z","article-title":"Combination therapy for onychomycosis using a fractional 2940-nm Er:YAG laser and 5% amorolfine lacquer","volume":"31","author":"Zhang","year":"2016","journal-title":"Lasers Med Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/jdv.13842","article-title":"Methyl aminolevulinate photodynamic therapy for onychomycosis: A multicenter, randomized, controlled clinical trial","volume":"31","author":"Gilaberte","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1590\/abd1806-4841.20142197","article-title":"Distal and lateral toenail onychomycosis caused by Trichophyton rubrum: Treatment with photodynamic therapy based on methylene blue dye","volume":"89","author":"Souza","year":"2014","journal-title":"An. Bras Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S0190-9622(08)81273-X","article-title":"Topical and surgical treatment of onychomycosis","volume":"31","author":"Cohen","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1473-2130.2004.00095.x","article-title":"Nail abrasion","volume":"2","author":"Kadunc","year":"2003","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.jfas.2008.12.012","article-title":"Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: A randomized, controlled trial","volume":"48","author":"Malay","year":"2009","journal-title":"J. Foot Ankle Surg."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7547\/0960465","article-title":"Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial","volume":"96","author":"Jennings","year":"2006","journal-title":"J. Am. Podiatr. Med. Assoc."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/09546634.2016.1151856","article-title":"An open comparative study of nail drilling as adjunctive treatment for toenail onychomycosis","volume":"27","author":"Shemer","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/09546630701657187","article-title":"Review of antifungal therapy, part II: Treatment rationale, including specific patient populations","volume":"19","author":"Baran","year":"2008","journal-title":"J. Dermatol. Treat."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaad.2016.02.1154","article-title":"Chronic paronychia treatment: Square flap technique","volume":"75","author":"Papaiordanou","year":"2016","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/4\/3\/99\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:19:41Z","timestamp":1760195981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/4\/3\/99"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,20]]},"references-count":97,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["jof4030099"],"URL":"https:\/\/doi.org\/10.3390\/jof4030099","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734076593.793561584","asserted-by":"object"}]},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,20]]}}}